|
Site Search
|
Medigen In-licenses Asian Rights for Cancer Drug
publication date: Mar 19, 2008
Medigen Biotechnology Corp., a biotech company based in Taiwan, has in-licensed key rights for a cancer drug from Oncolys BioPharma, Inc. of Japan. Medigen will pay up to $198.9 million, including milestones, for the right to develop OBP-301 for liver cancer or an alternative indication. Plus, upon completing Phase II studies, Medigen will also have the option to acquire the Asian rights, including China and Japan, to the drug for all indications. More details...
|
Partner Events
October 11-13, 2008
Dalian, China
November 08, 2008
The Institute of Americas, UCSDa
November 9-11, 2008
Shanghai, China
February 23-25, 2009
San Diego
>> More details...
|